<p>TIAA 信託國家協會根據最新提交給證券交易委員會的 13F 文件顯示，在第一季度增持了百時美施貴寶（Bristol-Myers Squibb，NYSE:BMY - 免費報告）的股份，持股增長了 245.5%。該機構投資者在此期間額外增持了 298,026 股，持有這家生物製藥公司的股份達 419,445 股。TIAA 信託國家協會在最新報告期結束時持有的百時美施貴寶股份價值 2274.7 萬美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
<ul>
<li>3 只高股息股票，現在收入，未來增長</li>
</ul>
<p>其他對沖基金最近也買賣了該公司的股票。挪威中央銀行在第四季度購入了百時美施貴寶股份，價值約 15.60524 億美元。M&amp;G Plc 在第一季度購入了百時美施貴寶股份，價值約 3.92608 億美元。Pzena 投資管理公司在第一季度將其百時美施貴寶股份增加了 119.8%。Pzena 投資管理公司現在擁有 1229.3913 萬股這家生物製藥公司的股份，價值 6.66699 億美元，比上一季度增持了 670.1097 萬股。Van ECK Associates Corp 在第一季度將其百時美施貴寶股份增加了 97.2%。Van ECK Associates Corp 現在擁有 794.9173 萬股這家生物製藥公司的股份，價值 4.31084 億美元，比上一季度增持了 391.8234 萬股。最後，Primecap Management Co. CA 在第四季度將其百時美施貴寶股份增加了 14.6%。Primecap Management Co. CA 現在擁有 2353.4378 萬股這家生物製藥公司的股份，價值 12.07549 億美元，比上一季度增持了 299.8228 萬股。76.41% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些股票研究分析師最近對 BMY 股票發表了意見。William Blair 在 4 月 1 日星期一的研究報告中重申了對百時美施貴寶股票的 “市場表現” 評級。BMO Capital Markets 將百時美施貴寶的目標股價從 55.00 美元降至 48.00 美元，並在 4 月 26 日星期五的研究報告中給予該股票 “市場表現” 評級。StockNews.com 在 6 月 27 日星期四的研究報告中，將百時美施貴寶股票的評級從 “強熱門” 調降至 “買入”。富國銀行（Wells Fargo &amp; Company）將百時美施貴寶的目標股價從 51.00 美元上調至 52.00 美元，並在 4 月 18 日星期四的研究報告中給予該公司 “等權重” 評級。最後，巴克萊將百時美施貴寶的目標股價從 43.00 美元降至 41.00 美元，並在 7 月 10 日星期三的研究報告中給予該股票 “等權重” 評級。一位股票研究分析師給予該股票賣出評級，十三位給予持有評級，四位給予買入評級。根據 MarketBeat.com 的數據，百時美施貴寶目前的平均評級為 “持有”，公司的共識目標股價為 59.07 美元。</p>
<p><strong>閲讀我們關於百時美施貴寶的最新研究報告</strong></p>
<h2>百時美施貴寶股票表現</h2>
<p>BMY 週五在午盤交易中上漲 0.25 美元，報 42.64 美元。該公司的股票交易量為 12,839,934 股，相比平均交易量 16,336,650 股。百時美施貴寶過去 12 個月的最低價為 39.35 美元，最高價為 65.38 美元。該股的市值為 864.4 億美元，市盈率為-13.75，PEG 比率為 15.55，貝塔係數為 0.44。該公司的 50 天簡單移動平均線為 41.68 美元，200 天簡單移動平均線為 47.02 美元。該公司的流動比率為 1.11，速動比率為 0.99，負債權益比率為 2.99。</p>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近公佈了截至 4 月 25 日星期四的季度財報。這家生物製藥公司報告本季度每股虧損 4.40 美元，超過了每股虧損 4.53 美元的共識預期 0.13 美元。百時美施貴寶的淨資產回報率為 8.83%，淨利潤率為-13.50%。該公司本季度營收為 118.7 億美元，高於分析師預期的 114.5 億美元。去年同期，該公司每股收益為 2.05 美元。與去年同期相比，百時美施貴寶本季度的營收增長了 4.7%。研究分析師預計，百時美施貴寶今年將實現每股收益 0.55 美元。</p>
<h2>百時美施貴寶股息公告</h2>
<p>該公司最近宣佈了季度股息，將於 8 月 1 日星期四支付。截至 7 月 5 日星期五的股東將獲得每股 0.60 美元的股息。這代表年度股息為 2.40 美元，股息率為 5.63%。除息日為 7 月 5 日星期五。百時美施貴寶的派息比率目前為-77.42%。</p>
<h2>百時美施貴寶公司簡介（免費報告）</h2>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。其產品涵蓋血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者的中風/全身栓塞風險，以及用於 DVT/PE 的治療；Opdivo，用於多種抗癌適應症，包括膀胱、血液、CRC、頭頸、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓性白血病的治療。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們比百時美施貴寶更喜歡的股票</li>
<li>投資商業服務股</li>
<li>為什麼這隻人工智能股票在科技拋售中上漲</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>投資者正在轉向債券和小盤股：原因在這裏</li>
<li>突破性股票：它們是什麼以及如何識別</li>
<li>MarketBeat 周評 - 7/15 - 7/19</li>
</ul>
<p><strong>想看看其他對百時美施貴寶持有什麼看法的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取百時美施貴寶（NYSE:BMY - 免費報告）的最新 13F 申報和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 揭秘：3 枚 CENT 加密貨幣將在 6 月 24 日爆發？（來自 True Market Insiders）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0"/></p>
<h2>現在是否值得投資$1,000 美元到百時美施貴寶？</h2>
<p>在考慮百時美施貴寶之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而百時美施貴寶不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

百時美施貴寶

<p>TIAA 信託國家協會在第一季度增持了百時美施貴寶 245.5% 的股份。其他對沖基金也購入了該公司的股票。幾位股票研究分析師最近對 BMY 股票發表了意見。百時美施貴寶的股價目前為 42.64 美元。該公司最近披露了季度股息</p>

<p>TIAA Trust National Association increased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 245.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,445 shares of the biopharmaceutical company's stock after acquiring an additional 298,026 shares during the period. TIAA Trust National Association's holdings in Bristol-Myers Squibb were worth $22,747,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>TIAA 信託國家協會根據最新提交給證券交易委員會的 13F 文件顯示，在第一季度增持了百時美施貴寶（Bristol-Myers Squibb，NYSE:BMY - 免費報告）的股份，持股增長了 245.5%。該機構投資者在此期間額外增持了 298,026 股，持有這家生物製藥公司的股份達 419,445 股。TIAA 信託國家協會在最新報告期結束時持有的百時美施貴寶股份價值 2274.7 萬美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
<ul>
<li>3 只高股息股票，現在收入，未來增長</li>
</ul>
</div><p>Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,560,524,000. M&amp;G Plc purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $392,608,000. Pzena Investment Management LLC raised its stake in shares of Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company's stock worth $666,699,000 after purchasing an additional 6,701,097 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Bristol-Myers Squibb by 97.2% during the 1st quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock worth $431,084,000 after purchasing an additional 3,918,234 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Bristol-Myers Squibb by 14.6% during the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company's stock worth $1,207,549,000 after purchasing an additional 2,998,228 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金最近也買賣了該公司的股票。挪威中央銀行在第四季度購入了百時美施貴寶股份，價值約 15.60524 億美元。M&amp;G Plc 在第一季度購入了百時美施貴寶股份，價值約 3.92608 億美元。Pzena 投資管理公司在第一季度將其百時美施貴寶股份增加了 119.8%。Pzena 投資管理公司現在擁有 1229.3913 萬股這家生物製藥公司的股份，價值 6.66699 億美元，比上一季度增持了 670.1097 萬股。Van ECK Associates Corp 在第一季度將其百時美施貴寶股份增加了 97.2%。Van ECK Associates Corp 現在擁有 794.9173 萬股這家生物製藥公司的股份，價值 4.31084 億美元，比上一季度增持了 391.8234 萬股。最後，Primecap Management Co. CA 在第四季度將其百時美施貴寶股份增加了 14.6%。Primecap Management Co. CA 現在擁有 2353.4378 萬股這家生物製藥公司的股份，價值 12.07549 億美元，比上一季度增持了 299.8228 萬股。76.41% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of equities research analysts have recently weighed in on BMY shares. William Blair reaffirmed a &#34;market perform&#34; rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Thursday, June 27th. Wells Fargo &amp; Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, April 18th. Finally, Barclays cut their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of &#34;Hold&#34; and a consensus price target of $59.07.</p>
<ul>
<li>Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore</li>
</ul>
<div class="lb-trans"><p>一些股票研究分析師最近對 BMY 股票發表了意見。William Blair 在 4 月 1 日星期一的研究報告中重申了對百時美施貴寶股票的 “市場表現” 評級。BMO Capital Markets 將百時美施貴寶的目標股價從 55.00 美元降至 48.00 美元，並在 4 月 26 日星期五的研究報告中給予該股票 “市場表現” 評級。StockNews.com 在 6 月 27 日星期四的研究報告中，將百時美施貴寶股票的評級從 “強熱門” 調降至 “買入”。富國銀行（Wells Fargo &amp; Company）將百時美施貴寶的目標股價從 51.00 美元上調至 52.00 美元，並在 4 月 18 日星期四的研究報告中給予該公司 “等權重” 評級。最後，巴克萊將百時美施貴寶的目標股價從 43.00 美元降至 41.00 美元，並在 7 月 10 日星期三的研究報告中給予該股票 “等權重” 評級。一位股票研究分析師給予該股票賣出評級，十三位給予持有評級，四位給予買入評級。根據 MarketBeat.com 的數據，百時美施貴寶目前的平均評級為 “持有”，公司的共識目標股價為 59.07 美元。</p>
</div><p><strong>Read Our Latest Research Report on Bristol-Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於百時美施貴寶的最新研究報告</strong></p>
</div><h2>Bristol-Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶股票表現</h2>
</div><p>BMY traded up $0.25 during midday trading on Friday, reaching $42.64. The company's stock had a trading volume of 12,839,934 shares, compared to its average volume of 16,336,650. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $65.38. The stock has a market cap of $86.44 billion, a P/E ratio of -13.75, a PEG ratio of 15.55 and a beta of 0.44. The company has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $47.02. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>BMY 週五在午盤交易中上漲 0.25 美元，報 42.64 美元。該公司的股票交易量為 12,839,934 股，相比平均交易量 16,336,650 股。百時美施貴寶過去 12 個月的最低價為 39.35 美元，最高價為 65.38 美元。該股的市值為 864.4 億美元，市盈率為-13.75，PEG 比率為 15.55，貝塔係數為 0.44。該公司的 50 天簡單移動平均線為 41.68 美元，200 天簡單移動平均線為 47.02 美元。該公司的流動比率為 1.11，速動比率為 0.99，負債權益比率為 2.99。</p>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the firm earned $2.05 EPS. Bristol-Myers Squibb's revenue for the quarter was up 4.7% compared to the same quarter last year. Research analysts expect that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近公佈了截至 4 月 25 日星期四的季度財報。這家生物製藥公司報告本季度每股虧損 4.40 美元，超過了每股虧損 4.53 美元的共識預期 0.13 美元。百時美施貴寶的淨資產回報率為 8.83%，淨利潤率為-13.50%。該公司本季度營收為 118.7 億美元，高於分析師預期的 114.5 億美元。去年同期，該公司每股收益為 2.05 美元。與去年同期相比，百時美施貴寶本季度的營收增長了 4.7%。研究分析師預計，百時美施貴寶今年將實現每股收益 0.55 美元。</p>
</div><h2>Bristol-Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百時美施貴寶股息公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.63%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb's payout ratio is presently -77.42%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 8 月 1 日星期四支付。截至 7 月 5 日星期五的股東將獲得每股 0.60 美元的股息。這代表年度股息為 2.40 美元，股息率為 5.63%。除息日為 7 月 5 日星期五。百時美施貴寶的派息比率目前為-77.42%。</p>
</div><h2>Bristol-Myers Squibb Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>百時美施貴寶公司簡介（免費報告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。其產品涵蓋血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者的中風/全身栓塞風險，以及用於 DVT/PE 的治療；Opdivo，用於多種抗癌適應症，包括膀胱、血液、CRC、頭頸、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓性白血病的治療。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Business Services Stocks Investing</li>
<li>Why This AI Stock is Rising Despite Tech Sell-Off</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Investors Are Moving into Bonds and Small Cap Stocks: Here's Why</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>MarketBeat Week in Review – 7/15 - 7/19</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>五隻我們比百時美施貴寶更喜歡的股票</li>
<li>投資商業服務股</li>
<li>為什麼這隻人工智能股票在科技拋售中上漲</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>投資者正在轉向債券和小盤股：原因在這裏</li>
<li>突破性股票：它們是什麼以及如何識別</li>
<li>MarketBeat 周評 - 7/15 - 7/19</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對百時美施貴寶持有什麼看法的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取百時美施貴寶（NYSE:BMY - 免費報告）的最新 13F 申報和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭秘：3 枚 CENT 加密貨幣將在 6 月 24 日爆發？（來自 True Market Insiders）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8484&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元到百時美施貴寶？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而百時美施貴寶不在名單上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

TIAA Trust National Association 增持了百時美施貴寶（NYSE:BMY）的股份